Low Molecular Weight Heparin Market - by Drug Type (Enoxaparin, Dalteparin, Tinzaparin, and Others), by Application (Venous Thromboembolism, Myocardial Infraction, Complicated Pregnancies, Cardioversion of Atrial Fibrillation, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2018-2026

  • To Be Published : Oct 2018 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin.  However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.

Low Molecular Weight Heparin Market Taxonomy

By Drug Type

  • Enoxaparin
  • Dalteparin
  • Tinzaparin
  • Others

By Application

  • Venous Thromboembolism
  • Myocardial Infraction
  • Complicated Pregnancies
  • Cardioversion of Atrial Fibrillation
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Low Molecular Weight Heparin Market Driver

Low molecular weight heparin market growth attributed to advantages of low molecular weight heparin over unfractionated heparin. Unfractionated heparin or standard heparin varies in action from patient to patient. Thus, it can only be administered by hospitalized patients under monitoring, while low molecular weight heparin can be used subcutaneously once a day,  without the need for monitoring. Furthermore, heparin is associated with serious side-effects such as Thrombocytopenia, heparin-induced thrombocytopenia (HIT), and heparin-induced thrombocytopenia and thrombosis (HITT). Such advantages of low molecular weight heparin over unfractionated heparin is boosting growth of the low molecular weight heparin market. Additionally, properties such as better bioavailability, predictable dose response, and longer plasma half-life than unfractionated heparin, makes low molecular weight heparin a better candidate for anticoagulant therapy. This in turn, is fuelling demand for low molecular weight heparin, thus expected to boost market growth over the forecast period (2017 – 2025).

Increasing inclination of research institutes towards developing novel alternatives for available LMWH treatments is expected to widen the range of therapies, while narrowing down its side effects. For example, American University of Beirut Medical Centre sponsored the study for a drug, bemiparin sodium (a form of LMWH), which is in phase 4 and is expected to be completed in mid-2018, to improve the pregnancy outcomes in patients with recurrent implantation failure undergoing IVF/ ICSI treatment. Additionally, companies are collaborating with hospitals to strengthen their product portfolio. For instance, Bayer in collaboration with Assistance Publique - Hopitaux de Paris is studying combination of rivaroxaban and low molecular weight heparin for neoplasm and venous thromboembolism, which is in phase 3. Both these pipeline drugs are expected to complete their final stages of study during the forecast period, which in turn is expected to enhance the low molecular weight heparin market.

Low molecular weight heparin is approved for the treatment of prophylaxis and orthopaedic surgeries, deep vein thrombosis, unstable angina, and complicated pregnancies. Thus, growing prevalence of these conditions is expected to increase demand for low molecular weight heparin market. For instance, according to Centers for Disease Control and Prevention (CDC, 2015), 900,000 people are affected by venous thromboembolism, each year in the U.S. Furthermore, 5% to 8% of the U.S. population has increased risk for thrombosis due to one of several genetic risk factors known as inherited thrombophilia. Thus, increasing demand for low molecular weight heparin in surgeries and for treating blood clotting disorders in turn, is expected to boost growth of the low molecular weight heparin market.

Low Molecular Weight Heparin Market - Competitors

Key player operating in the low molecular weight heparin market include Sanofi, Amphastar Pharmaceutical Inc., Teva Pharmaceuticals Industries Inc., Pfizer, Inc., LEO Pharmaceutical Products, Celgene Corporation, Sandoz GmbH (a division of Novartis AG), and Changzhou Qianhong Bio-pharma co. ltd.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.